Dr Berin Parambethu Varghese

Berin is a veterinary scientist with a strong academic and research background. 

He graduated in Veterinary Science and Animal Husbandry from Kerala Veterinary and Animal Sciences University in 2012, and then obtained his postgraduate degree in veterinary pathology from the Indian Veterinary Research Institute in 2014. 

In 2021, he earned his PhD in comparative biomedical sciences, specializing in molecular virology, from the University of Maryland, College Park, USA, where he focused on developing a non-Marek’s disease virus vectored vaccine against the infectious bursal disease virus. While at the University of Maryland, Berin also served as the A/BSL-3 Manager for the Gudelsky Veterinary Medicine high-containment suite. 

He has extensive research experience with CL3 pathogens, including avian influenza, Newcastle disease virus, and SARS-CoV-2. Prior to joining The Pirbright Institute, he worked as a scientist at GlaxoSmithKline (GSK) in the USA, where he worked on negative sense RNA viruses like respiratory syncytial virus and contributed to the development of self-amplifying RNA (SAM) and conventional RNA vaccine platforms targeting significant human pathogens.